CA2346768A1 - La phytomique: une methode genomique de concevoir des compositions a base de plantes - Google Patents
La phytomique: une methode genomique de concevoir des compositions a base de plantes Download PDFInfo
- Publication number
- CA2346768A1 CA2346768A1 CA002346768A CA2346768A CA2346768A1 CA 2346768 A1 CA2346768 A1 CA 2346768A1 CA 002346768 A CA002346768 A CA 002346768A CA 2346768 A CA2346768 A CA 2346768A CA 2346768 A1 CA2346768 A1 CA 2346768A1
- Authority
- CA
- Canada
- Prior art keywords
- herbal
- herbal composition
- batch
- hbr
- array
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 296
- 238000013459 approach Methods 0.000 title description 6
- 238000000034 method Methods 0.000 claims abstract description 113
- 238000003491 array Methods 0.000 claims abstract description 57
- 230000004071 biological effect Effects 0.000 claims abstract description 56
- 239000003814 drug Substances 0.000 claims abstract description 52
- 239000003550 marker Substances 0.000 claims abstract description 31
- 230000014509 gene expression Effects 0.000 claims description 61
- 239000000126 substance Substances 0.000 claims description 48
- 230000004044 response Effects 0.000 claims description 31
- 229940079593 drug Drugs 0.000 claims description 26
- 238000002360 preparation method Methods 0.000 claims description 26
- 210000000056 organ Anatomy 0.000 claims description 17
- 238000005259 measurement Methods 0.000 claims description 15
- 230000002596 correlated effect Effects 0.000 claims description 14
- 230000002068 genetic effect Effects 0.000 claims description 12
- 238000013461 design Methods 0.000 claims description 8
- 230000000877 morphologic effect Effects 0.000 claims description 8
- 230000009910 autonomic response Effects 0.000 claims description 6
- 230000002559 cytogenic effect Effects 0.000 claims description 6
- 230000006461 physiological response Effects 0.000 claims description 5
- 230000001149 cognitive effect Effects 0.000 claims description 4
- 238000000099 in vitro assay Methods 0.000 claims description 4
- 230000008512 biological response Effects 0.000 abstract description 24
- 238000011161 development Methods 0.000 abstract description 9
- 239000000470 constituent Substances 0.000 abstract description 6
- 230000001976 improved effect Effects 0.000 abstract description 4
- 210000004027 cell Anatomy 0.000 description 104
- 241000196324 Embryophyta Species 0.000 description 86
- 108090000623 proteins and genes Proteins 0.000 description 76
- 235000008216 herbs Nutrition 0.000 description 70
- 239000002904 solvent Substances 0.000 description 55
- 102000004169 proteins and genes Human genes 0.000 description 48
- 238000004458 analytical method Methods 0.000 description 43
- 240000004371 Panax ginseng Species 0.000 description 40
- 235000008434 ginseng Nutrition 0.000 description 40
- 230000000694 effects Effects 0.000 description 39
- 238000004128 high performance liquid chromatography Methods 0.000 description 37
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 35
- 235000003140 Panax quinquefolius Nutrition 0.000 description 35
- 238000012360 testing method Methods 0.000 description 35
- 239000000284 extract Substances 0.000 description 34
- 238000011282 treatment Methods 0.000 description 34
- 238000003556 assay Methods 0.000 description 33
- 108020004414 DNA Proteins 0.000 description 29
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 29
- 229910001868 water Inorganic materials 0.000 description 29
- 241000282414 Homo sapiens Species 0.000 description 27
- 241000411851 herbal medicine Species 0.000 description 26
- 108020004999 messenger RNA Proteins 0.000 description 25
- 239000000090 biomarker Substances 0.000 description 20
- 240000008693 Glycyrrhiza lepidota Species 0.000 description 19
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 18
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 18
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 18
- 238000004422 calculation algorithm Methods 0.000 description 18
- 235000015872 dietary supplement Nutrition 0.000 description 18
- 230000012010 growth Effects 0.000 description 18
- 229940010454 licorice Drugs 0.000 description 18
- 210000001519 tissue Anatomy 0.000 description 17
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- 238000002493 microarray Methods 0.000 description 15
- 241000700159 Rattus Species 0.000 description 14
- 238000005119 centrifugation Methods 0.000 description 14
- 238000005516 engineering process Methods 0.000 description 14
- 230000006870 function Effects 0.000 description 14
- 239000006228 supernatant Substances 0.000 description 14
- 230000001965 increasing effect Effects 0.000 description 13
- 238000004949 mass spectrometry Methods 0.000 description 13
- FXNFHKRTJBSTCS-UHFFFAOYSA-N baicalein Chemical compound C=1C(=O)C=2C(O)=C(O)C(O)=CC=2OC=1C1=CC=CC=C1 FXNFHKRTJBSTCS-UHFFFAOYSA-N 0.000 description 12
- 238000000018 DNA microarray Methods 0.000 description 11
- 241000736199 Paeonia Species 0.000 description 11
- 235000006484 Paeonia officinalis Nutrition 0.000 description 11
- 238000009826 distribution Methods 0.000 description 11
- 239000012676 herbal extract Substances 0.000 description 11
- 230000008569 process Effects 0.000 description 11
- 239000000523 sample Substances 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 10
- 150000001875 compounds Chemical class 0.000 description 10
- 238000010790 dilution Methods 0.000 description 10
- 239000012895 dilution Substances 0.000 description 10
- 201000010099 disease Diseases 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 230000036541 health Effects 0.000 description 10
- 230000005764 inhibitory process Effects 0.000 description 10
- KJFMBFZCATUALV-UHFFFAOYSA-N phenolphthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2C(=O)O1 KJFMBFZCATUALV-UHFFFAOYSA-N 0.000 description 10
- 229930182490 saponin Natural products 0.000 description 10
- 150000007949 saponins Chemical class 0.000 description 10
- 235000017709 saponins Nutrition 0.000 description 10
- 108091006146 Channels Proteins 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 239000002299 complementary DNA Substances 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 9
- 239000008485 shosaiko-to Substances 0.000 description 9
- 241000894007 species Species 0.000 description 9
- 231100000419 toxicity Toxicity 0.000 description 9
- 230000001988 toxicity Effects 0.000 description 9
- 241000588724 Escherichia coli Species 0.000 description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 8
- 241000700721 Hepatitis B virus Species 0.000 description 8
- 102000004890 Interleukin-8 Human genes 0.000 description 8
- 108090001007 Interleukin-8 Proteins 0.000 description 8
- 208000002193 Pain Diseases 0.000 description 8
- 238000004166 bioassay Methods 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 238000004113 cell culture Methods 0.000 description 8
- 230000018109 developmental process Effects 0.000 description 8
- 230000006698 induction Effects 0.000 description 8
- 230000004054 inflammatory process Effects 0.000 description 8
- 229940096397 interleukin-8 Drugs 0.000 description 8
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 8
- 210000004072 lung Anatomy 0.000 description 8
- 230000004048 modification Effects 0.000 description 8
- 238000012986 modification Methods 0.000 description 8
- 108090000765 processed proteins & peptides Proteins 0.000 description 8
- 238000011160 research Methods 0.000 description 8
- 230000028327 secretion Effects 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- 210000001835 viscera Anatomy 0.000 description 8
- 241000218671 Ephedra Species 0.000 description 7
- 206010061218 Inflammation Diseases 0.000 description 7
- 210000001744 T-lymphocyte Anatomy 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 208000002672 hepatitis B Diseases 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 229910052760 oxygen Inorganic materials 0.000 description 7
- 230000001105 regulatory effect Effects 0.000 description 7
- 230000019491 signal transduction Effects 0.000 description 7
- WVTKBKWTSCPRNU-KYJUHHDHSA-N (+)-Tetrandrine Chemical compound C([C@H]1C=2C=C(C(=CC=2CCN1C)OC)O1)C(C=C2)=CC=C2OC(=C2)C(OC)=CC=C2C[C@@H]2N(C)CCC3=CC(OC)=C(OC)C1=C23 WVTKBKWTSCPRNU-KYJUHHDHSA-N 0.000 description 6
- 201000009051 Embryonal Carcinoma Diseases 0.000 description 6
- -1 NfxB Proteins 0.000 description 6
- 108010026552 Proteome Proteins 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 238000000006 cell growth inhibition assay Methods 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 230000001419 dependent effect Effects 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 6
- 238000009396 hybridization Methods 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- 230000003993 interaction Effects 0.000 description 6
- 238000012544 monitoring process Methods 0.000 description 6
- 102000004196 processed proteins & peptides Human genes 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 238000003908 quality control method Methods 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 5
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 235000002789 Panax ginseng Nutrition 0.000 description 5
- 102100033571 Tissue-type plasminogen activator Human genes 0.000 description 5
- 229930013930 alkaloid Natural products 0.000 description 5
- 208000006673 asthma Diseases 0.000 description 5
- 230000008238 biochemical pathway Effects 0.000 description 5
- 230000010261 cell growth Effects 0.000 description 5
- 231100000673 dose–response relationship Toxicity 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 150000002500 ions Chemical class 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 150000007523 nucleic acids Chemical group 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 230000037361 pathway Effects 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 238000003672 processing method Methods 0.000 description 5
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 5
- 210000003491 skin Anatomy 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 238000001262 western blot Methods 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- LQIAZOCLNBBZQK-UHFFFAOYSA-N 1-(1,2-Diphosphanylethyl)pyrrolidin-2-one Chemical compound PCC(P)N1CCCC1=O LQIAZOCLNBBZQK-UHFFFAOYSA-N 0.000 description 4
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 4
- 206010011224 Cough Diseases 0.000 description 4
- 206010012735 Diarrhoea Diseases 0.000 description 4
- 108091060211 Expressed sequence tag Proteins 0.000 description 4
- 102000003676 Glucocorticoid Receptors Human genes 0.000 description 4
- 108090000079 Glucocorticoid Receptors Proteins 0.000 description 4
- 102000053187 Glucuronidase Human genes 0.000 description 4
- 108010060309 Glucuronidase Proteins 0.000 description 4
- 239000004471 Glycine Substances 0.000 description 4
- 241000238631 Hexapoda Species 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 4
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 4
- 108010002350 Interleukin-2 Proteins 0.000 description 4
- 102000000588 Interleukin-2 Human genes 0.000 description 4
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 4
- 206010037660 Pyrexia Diseases 0.000 description 4
- 208000005392 Spasm Diseases 0.000 description 4
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 4
- 230000002411 adverse Effects 0.000 description 4
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 4
- QMNWISYXSJWHRY-YLNUDOOFSA-N astragaloside IV Chemical compound O1[C@H](C(C)(O)C)CC[C@]1(C)[C@@H]1[C@@]2(C)CC[C@]34C[C@]4(CC[C@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)CO4)O)C4(C)C)[C@H]4[C@@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)C[C@H]3[C@]2(C)C[C@@H]1O QMNWISYXSJWHRY-YLNUDOOFSA-N 0.000 description 4
- YBHILYKTIRIUTE-UHFFFAOYSA-N berberine Chemical compound C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 YBHILYKTIRIUTE-UHFFFAOYSA-N 0.000 description 4
- 229940093265 berberine Drugs 0.000 description 4
- QISXPYZVZJBNDM-UHFFFAOYSA-N berberine Natural products COc1ccc2C=C3N(Cc2c1OC)C=Cc4cc5OCOc5cc34 QISXPYZVZJBNDM-UHFFFAOYSA-N 0.000 description 4
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 4
- 230000033228 biological regulation Effects 0.000 description 4
- 210000002798 bone marrow cell Anatomy 0.000 description 4
- 238000005251 capillar electrophoresis Methods 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 238000012512 characterization method Methods 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- YPHMISFOHDHNIV-FSZOTQKASA-N cycloheximide Chemical compound C1[C@@H](C)C[C@H](C)C(=O)[C@@H]1[C@H](O)CC1CC(=O)NC(=O)C1 YPHMISFOHDHNIV-FSZOTQKASA-N 0.000 description 4
- 238000007418 data mining Methods 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 235000019634 flavors Nutrition 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 238000010348 incorporation Methods 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 210000002540 macrophage Anatomy 0.000 description 4
- 210000001616 monocyte Anatomy 0.000 description 4
- 230000036284 oxygen consumption Effects 0.000 description 4
- 230000007170 pathology Effects 0.000 description 4
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 4
- 238000003752 polymerase chain reaction Methods 0.000 description 4
- 230000004481 post-translational protein modification Effects 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- 238000005728 strengthening Methods 0.000 description 4
- 239000013589 supplement Substances 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 239000008704 toki-shakuyaku-san Substances 0.000 description 4
- 102400000059 Arg-vasopressin Human genes 0.000 description 3
- 101800001144 Arg-vasopressin Proteins 0.000 description 3
- 244000223760 Cinnamomum zeylanicum Species 0.000 description 3
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 3
- 102000008178 Cyclin B1 Human genes 0.000 description 3
- 108010060385 Cyclin B1 Proteins 0.000 description 3
- 238000007399 DNA isolation Methods 0.000 description 3
- 238000001712 DNA sequencing Methods 0.000 description 3
- SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000008070 Interferon-gamma Human genes 0.000 description 3
- 108010074328 Interferon-gamma Proteins 0.000 description 3
- 108010057466 NF-kappa B Proteins 0.000 description 3
- 102000003945 NF-kappa B Human genes 0.000 description 3
- 239000004677 Nylon Substances 0.000 description 3
- IPQKDIRUZHOIOM-UHFFFAOYSA-N Oroxin A Natural products OC1C(O)C(O)C(CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IPQKDIRUZHOIOM-UHFFFAOYSA-N 0.000 description 3
- 241000180649 Panax notoginseng Species 0.000 description 3
- 102100027467 Pro-opiomelanocortin Human genes 0.000 description 3
- 238000002123 RNA extraction Methods 0.000 description 3
- 241000124033 Salix Species 0.000 description 3
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 230000006978 adaptation Effects 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 150000003797 alkaloid derivatives Chemical class 0.000 description 3
- 102000013529 alpha-Fetoproteins Human genes 0.000 description 3
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 3
- 210000001132 alveolar macrophage Anatomy 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- QMNWISYXSJWHRY-BCBPIKMJSA-N astragaloside IV Natural products CC(C)(O)[C@@H]1CC[C@@](C)(O1)[C@H]2[C@@H](O)C[C@@]3(C)[C@@H]4C[C@H](O[C@@H]5O[C@H](CO)[C@H](O)[C@@H](O)[C@H]5O)[C@H]6C(C)(C)[C@H](CC[C@@]67C[C@@]47CC[C@]23C)O[C@@H]8OC[C@@H](O)[C@H](O)[C@H]8O QMNWISYXSJWHRY-BCBPIKMJSA-N 0.000 description 3
- UDFLTIRFTXWNJO-UHFFFAOYSA-N baicalein Chemical compound O1C2=CC(=O)C(O)=C(O)C2=C(O)C=C1C1=CC=CC=C1 UDFLTIRFTXWNJO-UHFFFAOYSA-N 0.000 description 3
- 229940015301 baicalein Drugs 0.000 description 3
- AQHDANHUMGXSJZ-UHFFFAOYSA-N baicalin Natural products OC1C(O)C(C(O)CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 AQHDANHUMGXSJZ-UHFFFAOYSA-N 0.000 description 3
- IKIIZLYTISPENI-ZFORQUDYSA-N baicalin Chemical compound O1[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IKIIZLYTISPENI-ZFORQUDYSA-N 0.000 description 3
- 229960003321 baicalin Drugs 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 210000001124 body fluid Anatomy 0.000 description 3
- 239000010839 body fluid Substances 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 230000011712 cell development Effects 0.000 description 3
- 150000005829 chemical entities Chemical class 0.000 description 3
- 210000000349 chromosome Anatomy 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 235000017803 cinnamon Nutrition 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- PFKIBRPYVNVMRU-UHFFFAOYSA-N cyclosieversioside F Natural products CC(C)(O)C1COC(C)(C1)C2C(O)CC3(C)C4CC(OC5OC(CO)C(O)C(O)C5O)C6C(C)(C)C(CCC67CC47CCC23C)OC8OCC(O)C(O)C8O PFKIBRPYVNVMRU-UHFFFAOYSA-N 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 3
- SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 3
- 230000003828 downregulation Effects 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 210000002889 endothelial cell Anatomy 0.000 description 3
- 238000011985 exploratory data analysis Methods 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 238000004817 gas chromatography Methods 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 238000003306 harvesting Methods 0.000 description 3
- 239000009331 herbal preparation PC-SPES Substances 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000007689 inspection Methods 0.000 description 3
- 229960003130 interferon gamma Drugs 0.000 description 3
- 239000007928 intraperitoneal injection Substances 0.000 description 3
- 206010025482 malaise Diseases 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000012775 microarray technology Methods 0.000 description 3
- 230000011278 mitosis Effects 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 229920001778 nylon Polymers 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 244000045947 parasite Species 0.000 description 3
- 230000035479 physiological effects, processes and functions Effects 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 238000001243 protein synthesis Methods 0.000 description 3
- WVTKBKWTSCPRNU-UHFFFAOYSA-N rac-Tetrandrin Natural products O1C(C(=CC=2CCN3C)OC)=CC=2C3CC(C=C2)=CC=C2OC(=C2)C(OC)=CC=C2CC2N(C)CCC3=CC(OC)=C(OC)C1=C23 WVTKBKWTSCPRNU-UHFFFAOYSA-N 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 description 3
- 239000008535 sairei-to Substances 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 230000014616 translation Effects 0.000 description 3
- 238000000825 ultraviolet detection Methods 0.000 description 3
- 210000003606 umbilical vein Anatomy 0.000 description 3
- 238000012795 verification Methods 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 239000002023 wood Substances 0.000 description 3
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 241000045403 Astragalus propinquus Species 0.000 description 2
- 102100025878 C1q-related factor Human genes 0.000 description 2
- PBAYDYUZOSNJGU-UHFFFAOYSA-N Chelidonic acid Chemical compound OC(=O)C1=CC(=O)C=C(C(O)=O)O1 PBAYDYUZOSNJGU-UHFFFAOYSA-N 0.000 description 2
- BWUQAWCUJMATJS-HNNXBMFYSA-N Coreximine Chemical compound C1C2=CC(OC)=C(O)C=C2C[C@@H]2N1CCC1=C2C=C(O)C(OC)=C1 BWUQAWCUJMATJS-HNNXBMFYSA-N 0.000 description 2
- 101800000414 Corticotropin Proteins 0.000 description 2
- 230000006820 DNA synthesis Effects 0.000 description 2
- 102400000686 Endothelin-1 Human genes 0.000 description 2
- 101800004490 Endothelin-1 Proteins 0.000 description 2
- 208000004232 Enteritis Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 235000016622 Filipendula ulmaria Nutrition 0.000 description 2
- 244000061544 Filipendula vulgaris Species 0.000 description 2
- 235000009664 Gliricidia sepium Nutrition 0.000 description 2
- 244000212127 Gliricidia sepium Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 241000202807 Glycyrrhiza Species 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 208000008454 Hyperhidrosis Diseases 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 102000004125 Interleukin-1alpha Human genes 0.000 description 2
- 108010082786 Interleukin-1alpha Proteins 0.000 description 2
- 102000010789 Interleukin-2 Receptors Human genes 0.000 description 2
- 108010038453 Interleukin-2 Receptors Proteins 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- MXTLAHSTUOXGQF-UHFFFAOYSA-O Jatrorrhizine Chemical compound COC1=CC=C2C=C3C(C=C(C(=C4)O)OC)=C4CC[N+]3=CC2=C1OC MXTLAHSTUOXGQF-UHFFFAOYSA-O 0.000 description 2
- 206010023126 Jaundice Diseases 0.000 description 2
- 208000007101 Muscle Cramp Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 206010029216 Nervousness Diseases 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 235000002791 Panax Nutrition 0.000 description 2
- 241000208343 Panax Species 0.000 description 2
- 241000168720 Panax japonicus Species 0.000 description 2
- 235000003143 Panax notoginseng Nutrition 0.000 description 2
- 102000010752 Plasminogen Inactivators Human genes 0.000 description 2
- 108010077971 Plasminogen Inactivators Proteins 0.000 description 2
- 241000219000 Populus Species 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 235000009827 Prunus armeniaca Nutrition 0.000 description 2
- 244000018633 Prunus armeniaca Species 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 108050006955 Tissue-type plasminogen activator Proteins 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 238000001467 acupuncture Methods 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 235000006533 astragalus Nutrition 0.000 description 2
- 238000000376 autoradiography Methods 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 210000000941 bile Anatomy 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 244000309464 bull Species 0.000 description 2
- 230000004856 capillary permeability Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 230000022131 cell cycle Effects 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000000795 chinese herbal drug Substances 0.000 description 2
- 208000020832 chronic kidney disease Diseases 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 102000006834 complement receptors Human genes 0.000 description 2
- 108010047295 complement receptors Proteins 0.000 description 2
- 239000002361 compost Substances 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 2
- 229960000258 corticotropin Drugs 0.000 description 2
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 2
- 208000013219 diaphoresis Diseases 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 230000001882 diuretic effect Effects 0.000 description 2
- 208000001848 dysentery Diseases 0.000 description 2
- 201000006549 dyspepsia Diseases 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 210000005175 epidermal keratinocyte Anatomy 0.000 description 2
- 230000001076 estrogenic effect Effects 0.000 description 2
- 239000003337 fertilizer Substances 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 229930182494 ginsenoside Natural products 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 238000011194 good manufacturing practice Methods 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 229910001385 heavy metal Inorganic materials 0.000 description 2
- 238000005534 hematocrit Methods 0.000 description 2
- 210000004295 hippocampal neuron Anatomy 0.000 description 2
- 208000013403 hyperactivity Diseases 0.000 description 2
- 210000003016 hypothalamus Anatomy 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000000411 inducer Substances 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- LTINPJMVDKPJJI-UHFFFAOYSA-N iodinated glycerol Chemical compound CC(I)C1OCC(CO)O1 LTINPJMVDKPJJI-UHFFFAOYSA-N 0.000 description 2
- 210000003041 ligament Anatomy 0.000 description 2
- 231100000053 low toxicity Toxicity 0.000 description 2
- 210000003810 lymphokine-activated killer cell Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000013507 mapping Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000003147 molecular marker Substances 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 239000002797 plasminogen activator inhibitor Substances 0.000 description 2
- 230000001323 posttranslational effect Effects 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000001103 potassium chloride Substances 0.000 description 2
- 235000011164 potassium chloride Nutrition 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000004445 quantitative analysis Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 238000003196 serial analysis of gene expression Methods 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000004611 spectroscopical analysis Methods 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 235000013616 tea Nutrition 0.000 description 2
- 230000002123 temporal effect Effects 0.000 description 2
- 210000002105 tongue Anatomy 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 210000003932 urinary bladder Anatomy 0.000 description 2
- 239000008916 wei-ling-xian Substances 0.000 description 2
- NTWLPZMPTFQYQI-UHFFFAOYSA-N (3alpha)-olean-12-ene-3,23-diol Natural products C1CC(O)C(C)(CO)C2CCC3(C)C4(C)CCC5(C)CCC(C)(C)CC5C4=CCC3C21C NTWLPZMPTFQYQI-UHFFFAOYSA-N 0.000 description 1
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 description 1
- YLRXAIKMLINXQY-ZDUSSCGKSA-O (S)-magnoflorine Chemical compound C1=C(OC)C(O)=C2C3=C(O)C(OC)=CC=C3C[C@@H]3[N+](C)(C)CCC1=C23 YLRXAIKMLINXQY-ZDUSSCGKSA-O 0.000 description 1
- UUOIRJWYUOKWPV-UHFFFAOYSA-N (diaminomethylideneamino) dihydrogen phosphate Chemical compound NC(N)=NOP(O)(O)=O UUOIRJWYUOKWPV-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- MUKYLHIZBOASDM-UHFFFAOYSA-N 2-[carbamimidoyl(methyl)amino]acetic acid 2,3,4,5,6-pentahydroxyhexanoic acid Chemical compound NC(=N)N(C)CC(O)=O.OCC(O)C(O)C(O)C(O)C(O)=O MUKYLHIZBOASDM-UHFFFAOYSA-N 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 1
- 102000011899 Aquaporin 2 Human genes 0.000 description 1
- 108010036221 Aquaporin 2 Proteins 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 206010003267 Arthritis reactive Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 206010063659 Aversion Diseases 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 206010007558 Cardiac failure chronic Diseases 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 101000957708 Catostomus commersonii Corticoliberin-2 Proteins 0.000 description 1
- 241000201841 Celosia Species 0.000 description 1
- 241000050051 Chelone glabra Species 0.000 description 1
- 108010058699 Choline O-acetyltransferase Proteins 0.000 description 1
- 102100023460 Choline O-acetyltransferase Human genes 0.000 description 1
- 241000207199 Citrus Species 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 102100036486 Cobalamin binding intrinsic factor Human genes 0.000 description 1
- 101710123904 Cobalamin binding intrinsic factor Proteins 0.000 description 1
- 241000007126 Codonopsis pilosula Species 0.000 description 1
- 241001133184 Colletotrichum agaves Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- ITUXKSNBORWKBO-UHFFFAOYSA-N Coptiside I Natural products COc1ccc(cc1)C2=CC(=O)c3c(O)cc(OC4OC(CO)C(O)C(O)C4OC5OC(CO)C(O)C(O)C5OC6OC(COC7OC(C)C(OC(=O)C)C(O)C7OC(=O)C)C(O)C(OC(=O)C)C6O)cc3O2 ITUXKSNBORWKBO-UHFFFAOYSA-N 0.000 description 1
- XDVZNDLANFJOQR-UHFFFAOYSA-N Coptisine Natural products O=Cc1c2OCOc2ccc1C=C3/NCCc4cc5OCOc5cc34 XDVZNDLANFJOQR-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 241000587240 Cynanchum Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 230000009946 DNA mutation Effects 0.000 description 1
- 241001523681 Dendrobium Species 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 240000001879 Digitalis lutea Species 0.000 description 1
- 101100346656 Drosophila melanogaster strat gene Proteins 0.000 description 1
- 101100261976 Drosophila melanogaster trk gene Proteins 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 241000723237 Ephedra intermedia Species 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 206010016717 Fistula Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 241000212941 Glehnia Species 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 235000000554 Glycyrrhiza uralensis Nutrition 0.000 description 1
- 240000008917 Glycyrrhiza uralensis Species 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- GCGBHJLBFAPRDB-UHFFFAOYSA-N Hederagenin Natural products CC1(C)CCC2(CCC3(C)C4CCC5C(C)(CO)C(O)CCC5(C)C4CC=C3C2C1)C(=O)O GCGBHJLBFAPRDB-UHFFFAOYSA-N 0.000 description 1
- 206010020112 Hirsutism Diseases 0.000 description 1
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 241001495448 Impatiens <genus> Species 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 241000488974 Loranthus Species 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- 241000701076 Macacine alphaherpesvirus 1 Species 0.000 description 1
- KYEAXNAYHSCLMT-CVVGWEDFSA-N Magnoflorine Natural products C[C@H]1OC=C2[C@@H]3[C@@H]1CN4CCc5c([nH]c6ccccc56)[C@@H]4[C@@H]3OC2=O KYEAXNAYHSCLMT-CVVGWEDFSA-N 0.000 description 1
- 235000019759 Maize starch Nutrition 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000158723 Melia Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 235000005135 Micromeria juliana Nutrition 0.000 description 1
- 102100024193 Mitogen-activated protein kinase 1 Human genes 0.000 description 1
- 108700015928 Mitogen-activated protein kinase 13 Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 235000003805 Musa ABB Group Nutrition 0.000 description 1
- 240000008790 Musa x paradisiaca Species 0.000 description 1
- 206010050031 Muscle strain Diseases 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- PYUSHNKNPOHWEZ-YFKPBYRVSA-N N-formyl-L-methionine Chemical compound CSCC[C@@H](C(O)=O)NC=O PYUSHNKNPOHWEZ-YFKPBYRVSA-N 0.000 description 1
- 206010029164 Nephrotic syndrome Diseases 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- 102000015336 Nerve Growth Factor Human genes 0.000 description 1
- 229930189092 Notoginsenoside Natural products 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 241001248610 Ophiocordyceps sinensis Species 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 235000008598 Paeonia lactiflora Nutrition 0.000 description 1
- 244000236658 Paeonia lactiflora Species 0.000 description 1
- YKRGDOXKVOZESV-WRJNSLSBSA-N Paeoniflorin Chemical group C([C@]12[C@H]3O[C@]4(O)C[C@](O3)([C@]1(C[C@@H]42)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)C)OC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-WRJNSLSBSA-N 0.000 description 1
- PTPHDVKWAYIFRX-UHFFFAOYSA-N Palmatine Natural products C1C2=C(OC)C(OC)=CC=C2C=C2N1CCC1=C2C=C(OC)C(OC)=C1 PTPHDVKWAYIFRX-UHFFFAOYSA-N 0.000 description 1
- 206010033664 Panic attack Diseases 0.000 description 1
- 206010034568 Peripheral coldness Diseases 0.000 description 1
- 241000972672 Phellodendron Species 0.000 description 1
- 241001674048 Phthiraptera Species 0.000 description 1
- 235000015266 Plantago major Nutrition 0.000 description 1
- 108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 description 1
- 102100039418 Plasminogen activator inhibitor 1 Human genes 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 244000197580 Poria cocos Species 0.000 description 1
- 235000008599 Poria cocos Nutrition 0.000 description 1
- 108010069820 Pro-Opiomelanocortin Proteins 0.000 description 1
- 239000000683 Pro-Opiomelanocortin Substances 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 102000007568 Proto-Oncogene Proteins c-fos Human genes 0.000 description 1
- 108010071563 Proto-Oncogene Proteins c-fos Proteins 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 238000010240 RT-PCR analysis Methods 0.000 description 1
- 101100517381 Rattus norvegicus Ntrk1 gene Proteins 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- NGFMICBWJRZIBI-JZRPKSSGSA-N Salicin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O1)c1c(CO)cccc1 NGFMICBWJRZIBI-JZRPKSSGSA-N 0.000 description 1
- 235000007315 Satureja hortensis Nutrition 0.000 description 1
- 240000002114 Satureja hortensis Species 0.000 description 1
- 101100537955 Schizosaccharomyces pombe (strain 972 / ATCC 24843) trk1 gene Proteins 0.000 description 1
- GCGBHJLBFAPRDB-KCVAUKQGSA-N Scutellaric acid Natural products CC1(C)CC[C@@]2(CC[C@@]3(C)[C@@H]4CC[C@H]5[C@@](C)(CO)[C@H](O)CC[C@]5(C)[C@H]4CC=C3[C@@H]2C1)C(=O)O GCGBHJLBFAPRDB-KCVAUKQGSA-N 0.000 description 1
- 241001077909 Sigesbeckia Species 0.000 description 1
- 241000258242 Siphonaptera Species 0.000 description 1
- 206010072170 Skin wound Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 241000362909 Smilax <beetle> Species 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- 206010041277 Sodium retention Diseases 0.000 description 1
- 241000219784 Sophora Species 0.000 description 1
- 241001671204 Stemona Species 0.000 description 1
- 241001330502 Stephania Species 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 241000202349 Taxus brevifolia Species 0.000 description 1
- OEGWOBMNQDATKP-UHFFFAOYSA-O Thalifendine Natural products C12=CC=3OCOC=3C=C2CC[N+]2=C1C=C1C=CC(O)=C(OC)C1=C2 OEGWOBMNQDATKP-UHFFFAOYSA-O 0.000 description 1
- 241000133430 Tinospora Species 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 241000819233 Tribulus <sea snail> Species 0.000 description 1
- 241000364021 Tulsa Species 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 102100031358 Urokinase-type plasminogen activator Human genes 0.000 description 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
- 102000004136 Vasopressin Receptors Human genes 0.000 description 1
- 108090000643 Vasopressin Receptors Proteins 0.000 description 1
- 208000010399 Wasting Syndrome Diseases 0.000 description 1
- 239000005862 Whey Substances 0.000 description 1
- 102000007544 Whey Proteins Human genes 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- 235000001978 Withania somnifera Nutrition 0.000 description 1
- 240000004482 Withania somnifera Species 0.000 description 1
- 241001492404 Woodchuck hepatitis virus Species 0.000 description 1
- LCXREBMNASQAOC-UHFFFAOYSA-N Worenine Chemical compound C1=C2C(C)=C(C=3C(=CC=4OCOC=4C=3)CC3)[N+]3=CC2=CC2=C1OCO2 LCXREBMNASQAOC-UHFFFAOYSA-N 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 101710185494 Zinc finger protein Proteins 0.000 description 1
- 102100023597 Zinc finger protein 816 Human genes 0.000 description 1
- 241000234314 Zingiber Species 0.000 description 1
- LUTSRLYCMSCGCS-BWOMAWGNSA-N [(3s,8r,9s,10r,13s)-10,13-dimethyl-17-oxo-1,2,3,4,7,8,9,11,12,16-decahydrocyclopenta[a]phenanthren-3-yl] acetate Chemical compound C([C@@H]12)C[C@]3(C)C(=O)CC=C3[C@@H]1CC=C1[C@]2(C)CC[C@H](OC(=O)C)C1 LUTSRLYCMSCGCS-BWOMAWGNSA-N 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000000642 acaricide Substances 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 229920001284 acidic polysaccharide Polymers 0.000 description 1
- 150000004805 acidic polysaccharides Chemical class 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- VLSMHEGGTFMBBZ-UHFFFAOYSA-N alpha-Kainic acid Natural products CC(=C)C1CNC(C(O)=O)C1CC(O)=O VLSMHEGGTFMBBZ-UHFFFAOYSA-N 0.000 description 1
- NGFMICBWJRZIBI-UHFFFAOYSA-N alpha-salicin Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=CC=C1CO NGFMICBWJRZIBI-UHFFFAOYSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 230000001142 anti-diarrhea Effects 0.000 description 1
- 230000003556 anti-epileptic effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 238000011091 antibody purification Methods 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 239000002948 appetite stimulant Substances 0.000 description 1
- 229910052785 arsenic Inorganic materials 0.000 description 1
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 230000002917 arthritic effect Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 238000013473 artificial intelligence Methods 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000001746 atrial effect Effects 0.000 description 1
- 238000002555 auscultation Methods 0.000 description 1
- 230000003305 autocrine Effects 0.000 description 1
- 210000003403 autonomic nervous system Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 235000021028 berry Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 229940097217 cardiac glycoside Drugs 0.000 description 1
- 239000002368 cardiac glycoside Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 230000004715 cellular signal transduction Effects 0.000 description 1
- 230000007541 cellular toxicity Effects 0.000 description 1
- 210000002230 centromere Anatomy 0.000 description 1
- 238000009614 chemical analysis method Methods 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 238000007705 chemical test Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 238000007621 cluster analysis Methods 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 230000006998 cognitive state Effects 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- CYOURJWVXZHEPP-UHFFFAOYSA-N columbamine Natural products COc1cc2CCN3Cc4c(OC)c(OC)ccc4C=C3c2cc1O CYOURJWVXZHEPP-UHFFFAOYSA-N 0.000 description 1
- YYFOFDHQVIODOQ-UHFFFAOYSA-O columbamine Chemical compound COC1=CC=C2C=C(C3=C(C=C(C(=C3)O)OC)CC3)[N+]3=CC2=C1OC YYFOFDHQVIODOQ-UHFFFAOYSA-O 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000010205 computational analysis Methods 0.000 description 1
- 238000000205 computational method Methods 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- LUXPUVKJHVUJAV-UHFFFAOYSA-M coptisine, chloride Chemical compound [Cl-].C1=C2C=C(C3=C(C=C4OCOC4=C3)CC3)[N+]3=CC2=C2OCOC2=C1 LUXPUVKJHVUJAV-UHFFFAOYSA-M 0.000 description 1
- VTOBHWOZXDRRAP-UHFFFAOYSA-N coreximine Natural products OC1=C(OC)C=C2C(=O)N3CCC(C=C(C(=C4)O)OC)=C4C3CC2=C1 VTOBHWOZXDRRAP-UHFFFAOYSA-N 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000011496 digital image analysis Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000012912 drug discovery process Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 201000000523 end stage renal failure Diseases 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- ZUBDGKVDJUIMQQ-ZTNLKOGPSA-N endothelin i Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CSSC[C@@H](C(N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-ZTNLKOGPSA-N 0.000 description 1
- 230000000688 enterotoxigenic effect Effects 0.000 description 1
- 229960002179 ephedrine Drugs 0.000 description 1
- FPJQGFLUORYYPE-UHFFFAOYSA-N epiberberine Chemical compound C1=C2C=C(C3=C(C=C(C(=C3)OC)OC)CC3)[N+]3=CC2=C2OCOC2=C1 FPJQGFLUORYYPE-UHFFFAOYSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 description 1
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 description 1
- 229940114124 ferulic acid Drugs 0.000 description 1
- 235000001785 ferulic acid Nutrition 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 230000003480 fibrinolytic effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 230000022244 formylation Effects 0.000 description 1
- 238000006170 formylation reaction Methods 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 239000000417 fungicide Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 229940089161 ginsenoside Drugs 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 230000034659 glycolysis Effects 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical group O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 230000007085 granulocyte colony-stimulating factor production Effects 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000003630 growth substance Substances 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 230000003779 hair growth Effects 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 208000024798 heartburn Diseases 0.000 description 1
- PGOYMURMZNDHNS-MYPRUECHSA-N hederagenin Chemical compound C1C[C@H](O)[C@@](C)(CO)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C PGOYMURMZNDHNS-MYPRUECHSA-N 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 239000000321 herbal drug Substances 0.000 description 1
- 239000008361 herbal raw material Substances 0.000 description 1
- 235000015092 herbal tea Nutrition 0.000 description 1
- 239000004009 herbicide Substances 0.000 description 1
- 230000000971 hippocampal effect Effects 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000002267 hypothalamic effect Effects 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 229930190166 impatien Natural products 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000002917 insecticide Substances 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000021995 interleukin-8 production Effects 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 238000012804 iterative process Methods 0.000 description 1
- 208000018937 joint inflammation Diseases 0.000 description 1
- VLSMHEGGTFMBBZ-OOZYFLPDSA-N kainic acid Chemical compound CC(=C)[C@H]1CN[C@H](C(O)=O)[C@H]1CC(O)=O VLSMHEGGTFMBBZ-OOZYFLPDSA-N 0.000 description 1
- 229950006874 kainic acid Drugs 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 238000012177 large-scale sequencing Methods 0.000 description 1
- 208000008127 lead poisoning Diseases 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 229940069445 licorice extract Drugs 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000010801 machine learning Methods 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000021121 meiosis Effects 0.000 description 1
- 230000003923 mental ability Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000006996 mental state Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 238000005065 mining Methods 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 150000004712 monophosphates Chemical class 0.000 description 1
- 230000008450 motivation Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000001491 myopia Diseases 0.000 description 1
- 230000004379 myopia Effects 0.000 description 1
- 230000036562 nail growth Effects 0.000 description 1
- 201000003631 narcolepsy Diseases 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 229940053128 nerve growth factor Drugs 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000001956 neutron scattering Methods 0.000 description 1
- 239000002687 nonaqueous vehicle Substances 0.000 description 1
- 231100000028 nontoxic concentration Toxicity 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 238000002966 oligonucleotide array Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229940124595 oriental medicine Drugs 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000005022 packaging material Substances 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- YKRGDOXKVOZESV-UHFFFAOYSA-N paeoniflorin Natural products O1C(C)(C2(CC34)OC5C(C(O)C(O)C(CO)O5)O)CC3(O)OC1C24COC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-UHFFFAOYSA-N 0.000 description 1
- QUCQEUCGKKTEBI-UHFFFAOYSA-N palmatine Chemical compound COC1=CC=C2C=C(C3=C(C=C(C(=C3)OC)OC)CC3)[N+]3=CC2=C1OC QUCQEUCGKKTEBI-UHFFFAOYSA-N 0.000 description 1
- 238000002559 palpation Methods 0.000 description 1
- 208000019906 panic disease Diseases 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 238000003909 pattern recognition Methods 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000000206 photolithography Methods 0.000 description 1
- 230000036314 physical performance Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 230000019330 positive regulation of interleukin-8 production Effects 0.000 description 1
- 235000015320 potassium carbonate Nutrition 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 238000007639 printing Methods 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical class CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 201000001514 prostate carcinoma Diseases 0.000 description 1
- 238000000164 protein isolation Methods 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 238000000734 protein sequencing Methods 0.000 description 1
- KWGRBVOPPLSCSI-WCBMZHEXSA-N pseudoephedrine Chemical compound CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WCBMZHEXSA-N 0.000 description 1
- 229960003908 pseudoephedrine Drugs 0.000 description 1
- BALXUFOVQVENIU-KXNXZCPBSA-N pseudoephedrine hydrochloride Chemical compound [H+].[Cl-].CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 BALXUFOVQVENIU-KXNXZCPBSA-N 0.000 description 1
- 235000008954 quail grass Nutrition 0.000 description 1
- 238000004451 qualitative analysis Methods 0.000 description 1
- 238000001303 quality assessment method Methods 0.000 description 1
- 238000000275 quality assurance Methods 0.000 description 1
- BBFYUPYFXSSMNV-UHFFFAOYSA-N quercetin-7-o-galactoside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC(O)=C2C(=O)C(O)=C(C=3C=C(O)C(O)=CC=3)OC2=C1 BBFYUPYFXSSMNV-UHFFFAOYSA-N 0.000 description 1
- 208000002574 reactive arthritis Diseases 0.000 description 1
- 238000000611 regression analysis Methods 0.000 description 1
- 230000007363 regulatory process Effects 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 230000017610 release of virus from host Effects 0.000 description 1
- 210000005000 reproductive tract Anatomy 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229910052702 rhenium Inorganic materials 0.000 description 1
- 229910052703 rhodium Inorganic materials 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 229910021481 rutherfordium Inorganic materials 0.000 description 1
- NGFMICBWJRZIBI-UJPOAAIJSA-N salicin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=CC=C1CO NGFMICBWJRZIBI-UJPOAAIJSA-N 0.000 description 1
- 229940120668 salicin Drugs 0.000 description 1
- CQRYARSYNCAZFO-UHFFFAOYSA-N salicyl alcohol Chemical compound OCC1=CC=CC=C1O CQRYARSYNCAZFO-UHFFFAOYSA-N 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 150000003873 salicylate salts Chemical class 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000008786 sensory perception of smell Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 230000008470 skin growth Effects 0.000 description 1
- 208000011726 slow pulse Diseases 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- FJPYVLNWWICYDW-UHFFFAOYSA-M sodium;5,5-diphenylimidazolidin-1-ide-2,4-dione Chemical compound [Na+].O=C1[N-]C(=O)NC1(C=1C=CC=CC=1)C1=CC=CC=C1 FJPYVLNWWICYDW-UHFFFAOYSA-M 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000007103 stamina Effects 0.000 description 1
- 238000011301 standard therapy Methods 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 229930002534 steroid glycoside Natural products 0.000 description 1
- 150000008143 steroidal glycosides Chemical class 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- DEXCWVBNPJKCOQ-UHFFFAOYSA-N tetrahydropseudocoptisine Natural products C1=C2C3CC(C=C4OCOC4=C4)=C4CN3CCC2=CC2=C1OCO2 DEXCWVBNPJKCOQ-UHFFFAOYSA-N 0.000 description 1
- QKDAYMOWDPMRHC-UHFFFAOYSA-N thalifendine Chemical compound [Cl-].C12=CC=3OCOC=3C=C2CC[N+]2=C1C=C1C=CC(O)=C(OC)C1=C2 QKDAYMOWDPMRHC-UHFFFAOYSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000003971 tillage Methods 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000723 toxicological property Toxicity 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 229940047183 tribulus Drugs 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- ZRBGFWOXAQPDTH-UHFFFAOYSA-N umbellatine Natural products C1=C2C3=CC4=CC=C(OC)C(OC)=C4C(O)N3CCC2=CC2=C1OCO2 ZRBGFWOXAQPDTH-UHFFFAOYSA-N 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Medicines Containing Plant Substances (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
L'invention concerne des outils et méthodologies nécessaires pour fournir des orientations en vue de la normalisation de compositions à base de plantes, afin de déterminer les composants spécifiques d'une telle composition, qui sont responsables d'une activité biologique particulière, pour prévoir les activités biologiques d'une composition particulière à base de plantes, et pour mettre au point des thérapies améliorées faisant intervenir des plantes. Cette invention propose des outils et méthodologies permettant de créer, gérer, améliorer et utiliser des réseaux HBR (réseaux de réponse biologique faisant intervenir des plantes), qui constituent des ensembles de données associés à des compositions particulières à base de plantes. Les réseaux HBR selon l'invention peuvent comprendre des informations relatives aux paramètres liés aux plantes des constituants à base de plantes, ainsi que des informations sur les marqueurs et sur la réponse biologique recueillies à la suite de l'exposition d'un écosystème à la composition à base de plantes.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10543598P | 1998-10-23 | 1998-10-23 | |
| US60/105,435 | 1998-10-23 | ||
| PCT/US1999/024851 WO2000024934A1 (fr) | 1998-10-23 | 1999-10-22 | La phytomique: une methode genomique de concevoir des compositions a base de plantes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2346768A1 true CA2346768A1 (fr) | 2000-05-04 |
Family
ID=22305836
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002346768A Abandoned CA2346768A1 (fr) | 1998-10-23 | 1999-10-22 | La phytomique: une methode genomique de concevoir des compositions a base de plantes |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP1124991A1 (fr) |
| JP (1) | JP2003521226A (fr) |
| KR (1) | KR100470379B1 (fr) |
| CN (1) | CN1335892A (fr) |
| AU (1) | AU779424B2 (fr) |
| CA (1) | CA2346768A1 (fr) |
| DE (1) | DE1124991T1 (fr) |
| ES (1) | ES2171371T1 (fr) |
| HK (1) | HK1039964A1 (fr) |
| WO (1) | WO2000024934A1 (fr) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001066803A2 (fr) * | 2000-03-09 | 2001-09-13 | Yale University | La phytomique: un procede genomique de concevoir des compositions a base de plantes |
| JP2006000113A (ja) * | 2004-05-20 | 2006-01-05 | Masatomo Sakurai | 漢方医療の診断に用いる遺伝子およびその利用方法 |
| KR102680200B1 (ko) * | 2016-06-22 | 2024-07-02 | 예일 유니버시티 | 식물 의약을 위한 메커니즘 기반 품질 관리 |
| CN108841928B (zh) * | 2018-06-11 | 2021-11-23 | 河北医科大学 | 一种人类线粒体基因组甲基化检测试剂盒及其应用 |
| CN110646497B (zh) * | 2018-06-27 | 2021-10-29 | 中国科学院沈阳应用生态研究所 | 一种通过稳定氮同位素比值鉴定有机农产品的方法 |
| CN110907580B (zh) * | 2019-12-20 | 2022-02-25 | 厦门中药厂有限公司 | 一种保元汤的hplc特征图谱的检测方法 |
| CN112305133B (zh) * | 2020-12-25 | 2022-05-24 | 成都普思生物科技股份有限公司 | 一种测定天葵子中唐松草酚定含量的方法 |
| CN112575005A (zh) * | 2021-01-04 | 2021-03-30 | 昆明理工大学 | 一种提高烟草重金属镉胁迫抗性和降低镉富集的方法 |
| CN114864016A (zh) * | 2022-03-25 | 2022-08-05 | 广西壮族自治区药用植物园 | 一种药用植物化合物信息数据库建立方法及系统 |
| JP7654293B1 (ja) * | 2024-06-17 | 2025-04-01 | バイオ - セラピー、フィジオロジカル システムズ フォー ヘルス ソシエタ ペル アチオニ | 天然の治療用の製品又は有益な製品がその治療的な効果又は有益な効果を生理的な作用機構を介して発揮する時期を決定するための方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997027317A1 (fr) * | 1996-01-23 | 1997-07-31 | Affymetrix, Inc. | Evaluation rapide de difference d'abondance d'acides nucleiques, avec un systeme d'oligonucleotides haute densite |
| US5569588A (en) * | 1995-08-09 | 1996-10-29 | The Regents Of The University Of California | Methods for drug screening |
| US5777888A (en) * | 1995-08-09 | 1998-07-07 | Regents Of The University Of California | Systems for generating and analyzing stimulus-response output signal matrices |
| WO1997013877A1 (fr) * | 1995-10-12 | 1997-04-17 | Lynx Therapeutics, Inc. | Mesure de profils d'expression genique pour evaluer la toxicite |
| WO2000003725A1 (fr) * | 1998-07-14 | 2000-01-27 | Paracelsian, Inc. | Procede d'identification et de confirmation de biofonctionnalite constante de compositions naturelles |
| US6780596B2 (en) * | 1998-09-17 | 2004-08-24 | Ashni Naturaceuticals, Inc. | Methods for determining the activity of complex mixtures |
-
1999
- 1999-10-22 EP EP99971046A patent/EP1124991A1/fr not_active Withdrawn
- 1999-10-22 WO PCT/US1999/024851 patent/WO2000024934A1/fr not_active Ceased
- 1999-10-22 CA CA002346768A patent/CA2346768A1/fr not_active Abandoned
- 1999-10-22 KR KR10-2001-7005096A patent/KR100470379B1/ko not_active Expired - Fee Related
- 1999-10-22 DE DE1124991T patent/DE1124991T1/de active Pending
- 1999-10-22 HK HK02101168.2A patent/HK1039964A1/zh unknown
- 1999-10-22 CN CN99815015A patent/CN1335892A/zh active Pending
- 1999-10-22 ES ES99971046T patent/ES2171371T1/es active Pending
- 1999-10-22 AU AU12249/00A patent/AU779424B2/en not_active Ceased
- 1999-10-22 JP JP2000578486A patent/JP2003521226A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR100470379B1 (ko) | 2005-02-07 |
| JP2003521226A (ja) | 2003-07-15 |
| AU1224900A (en) | 2000-05-15 |
| CN1335892A (zh) | 2002-02-13 |
| WO2000024934A1 (fr) | 2000-05-04 |
| KR20010099741A (ko) | 2001-11-09 |
| EP1124991A1 (fr) | 2001-08-22 |
| ES2171371T1 (es) | 2002-09-16 |
| HK1039964A1 (zh) | 2002-05-17 |
| AU779424B2 (en) | 2005-01-27 |
| DE1124991T1 (de) | 2002-08-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI275792B (en) | Matrix methods for quantitatively analyzing and assessing the properties of botanical samples | |
| Smelcerovic et al. | Phytochemical analysis and genetic characterization of six Hypericum species from Serbia | |
| US20030207270A1 (en) | Phytomics: a genomic-based approach to herbal compositions | |
| Jiang et al. | Identification of potential anti-pneumonia pharmacological components of Glycyrrhizae Radix et Rhizoma after the treatment with Gan An He Ji oral liquid | |
| Zhou et al. | Comparison and evaluation of antimuscarinic and anti-inflammatory effects of five Bulbus fritillariae species based on UPLC-Q/TOF integrated dual-luciferase reporter assay, PCA and ANN analysis | |
| Mao et al. | Combining transcriptomic analysis and network pharmacology to explore the mechanism by which Shaofu Zhuyu decoction improves diabetes mellitus erectile dysfunction | |
| Wang et al. | In vivo and in vitro study on the regulatory mechanism of XiaoChaiHu decoction on PANoptosis in sepsis-induced cardiomyopathy | |
| Qu et al. | Transcriptome profiling revealed the potential mechanisms of Shen Lin Bai Zhu San n-butanol extract on DSS induced colitis in mice and LC-MS analysis | |
| AU779424B2 (en) | Phytomics: a genomic-based approach to herbal compositions | |
| Li et al. | Clinical trait-connected network analysis reveals transcriptional markers of active psoriasis treatment with Liangxue-Jiedu decoction | |
| AU4556501A (en) | Phytomics: a genomic-based approach to herbal compositions | |
| Abdelmigid | New trends in genotoxicity testing of herbal medicinal plants | |
| Wen et al. | Correlation analysis between genetic and chemical differences of Nardostachys jatamansi from different habitats in Ganzi Tibetan Autonomous Prefecture, Sichuan Province, China | |
| Cho et al. | Combination of UHPLC-MS/MS with context-specific network and cheminformatic approaches for identifying bioactivities and active components of propolis | |
| US20010039022A1 (en) | Methods for determining the activity of complex mixtures | |
| AU2005201751A1 (en) | Phytomics: a genomic-based approach to herbal compositions | |
| Zheng et al. | Shen-Ling-Bai-Zhu-San alleviates Crohn’s disease-like colitis by modulating fatty acid degradation via the peroxisome proliferation-activated receptor pathway: An integrated approach combining network pharmacology, microbiomics, metabolomics, proteomics, and experimental validation | |
| TWI243210B (en) | A quality control method for assessing herbal compositions | |
| Zhao et al. | Treatment of acute pharyngitis in rats with season tea decoctions from traditional Chinese medicine through a synergistic and subtle regulation of ARNTL and BHLHE40 | |
| Mirmazloum et al. | Glycoside content in Rhodiola rosea L.: dynamics and expression pattern of genes involved in the synthesis of rosavins | |
| Han et al. | Comparative analysis of the influence of Fructus Ligustri Lucidi on a rat lumbar disc herniation model | |
| Wang et al. | Puerarin ameliorates alcoholic liver disease by regulating intestinal flora and MAPK/Nrf2 signalling pathways | |
| Antoshechkin et al. | Analysis of effects of the herbal preparation Circulat on gene expression levels in cultured human fibroblasts | |
| Xu et al. | Xiaojianzhong decoction inhibits gastric cancer progression and enhances 5-Fu efficacy by regulating the MAPK and PI3K-AKT signaling pathway | |
| Lin et al. | Integrating transcriptomics and network pharmacology to reveal the effect and mechanism of Bai-Jie-Jing-Xie ointment on improving skin inflammation of psoriasis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued | ||
| FZDE | Discontinued |
Effective date: 20061023 |